CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Unicocell Biomed Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Unicocell Biomed Co Ltd
6F, No.65, Lane 77
Xing-ai Road, Neihu District.
Phone: +886 227922699p:+886 227922699 TAIPEI, 114  Taiwan Ticker: 67946794
Business Summary
Unicocell Biomed Co Ltd is mainly engaged in the research and development of new adipose stem cell drugs and the application of stem cell technology. The main products include stem cell secretin and cell testing services. The Company's current development projects are divided into human adipose-derived mesenchymal stem cells, autologous adipose stem cell transplantation and cell preparation application products. The clinical trials of human adipose-derived mesenchymal stem cells include the ELIXCYTE-CT21 clinical trial project and the ELIXCYTE-CT31 clinical trial project. Autologous adipose stem cell transplantation is used for large-area burns and difficult wound healing. The cell preparation application products include stem cell secretin, which is a conditioned medium derived from cultured stem cells, used to improve skin dullness and fine lines.
(Source: N-30D)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Strategy Officer YiwenCai 5/5/2023 9/14/2018
Assistant General Manager of Finance & Accounting, Corporate Governance Officer PeilinChen 8/9/2024 8/28/2018
General Manager YipeiHong 7/29/2022 4/6/2021
6 additional Officers and Directors records available in full report.

General Information
Outstanding Shares: 58,385,000 (As of 9/30/2024)
Shareholders: 984
Stock Exchange: TPE
Fax Number: +886 227927890


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, December 3, 2024